The United States has launched an investigation under Section 301 trade authorities into Germany's pharmaceutical pricing and reimbursement practices. The probe examines whether these policies underpay for innovative medicines and place burdens on US commerce, following months of bilateral discussions. Reporting draws from France 24 and Anadolu Agency.
“US launches Germany pharma pricing probe, raising threat of new tariffs”
Read at France 24 →No center sources covered this
“US launches investigation into Germany's pharmaceutical pricing policies”
Read at Anadolu Agency →The probe prioritizes corporate profits over affordable medicine access and overlooks lessons from Germany's cost-effectiveness system.
“US patients subsidize global R&D due to high domestic prices”
The investigation correctly targets European price controls that allow underpayment for US-developed drugs and shift costs to American markets.
“Enforcing reciprocity against foreign underpricing”
Both German price controls and US tariff threats represent state coercion layered on existing regulatory distortions.
“Undermining voluntary exchange and free negotiation”
All perspectives accept without evidence that German prices fail to cover R&D costs and overlook Section 301's typical use for export barriers rather than reimbursement formulas.
“Shared premise that reference pricing equals free-riding”
Ratings by MBFC